We strongly support vaccination against COVID-19 with the Pfizer-BioNTech COVID-19 mRNA vaccine BNT162b2 when adhering to the 3-week dosing schedule that was found highly effective in the phase 3 randomised clinical trial—regarded as the gold standard. However we do not support the second dose being delayed to 12 weeks, as implemented by UK Chief Medical Officers.

National Health Service
Letter to chief executives of all NHS trusts and foundation trusts.